Current Development of Chemical Penetration Enhancers for Transdermal Insulin Delivery. 2023

Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
School of Medicine, Faculty of Health & Medical Sciences, Taylor's University, 1 Jalan Taylors, Subang Jaya 47500, Malaysia.

The use of the transdermal delivery system has recently gained ample recognition due to the ability to deliver drug molecules across the skin membrane, serving as an alternative to conventional oral or injectable routes. Subcutaneous insulin injection is the mainstay treatment for diabetes mellitus which often leads to non-compliance among patients, especially in younger patients. Apart from its invasiveness, the long-term consequences of insulin injection cause the development of physical trauma, which includes lipohypertrophy at the site of administration, scarring, infection, and sometimes nerve damage. Hence, there is a quest for a better alternative to drug delivery that is non-invasive and easily adaptable. One of the potential solutions is the transdermal delivery method. However, the stratum corneum (the top layer of skin) is the greatest barrier in transporting large molecules like insulin. Therefore, various chemical enhancers have been proposed to promote stratum corneum permeability, or they are designed to increase the permeability of the full epidermis, such as the use of ionic liquid, peptides, chemical pre-treatment as well as packaging insulin with carriers or nanoparticles. In this review, the recent progress in the development of chemical enhancers for transdermal insulin delivery is discussed along with the possible mechanistic of action and the potential outlook on the proposed permeation approaches in comparison to other therapeutical drugs.

UI MeSH Term Description Entries

Related Publications

Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
March 2005, Proceedings of the National Academy of Sciences of the United States of America,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
April 2012, Chemical biology & drug design,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
January 2015, Current drug delivery,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
June 2000, Current medicinal chemistry,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
January 1992, Acta pharmaceutica Nordica,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
November 2008, Pharmaceutical research,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
December 2016, Molecules (Basel, Switzerland),
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
September 2013, International journal of pharmaceutics,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
April 2009, Biological & pharmaceutical bulletin,
Vaisnevee Sugumar, and Maan Hayyan, and Priya Madhavan, and Won Fen Wong, and Chung Yeng Looi
February 1996, Indian journal of experimental biology,
Copied contents to your clipboard!